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Abstract 
 
Background: 
Infantile spasms are a severe infantile epilepsy syndrome that  is difficult to treat 
and have a high morbidity. Hormonal therapies or vigabatrin are the two 
treatments most commonly used. We investigated whether combining both 
treatments would be more effective than hormonal therapy alone.  
 
Methods: 
In this international, multi-centre, open-label randomised trial, 102 hospitals 
(Australia [3], Germany [11], New Zealand [2], Switzerland [3], and UK [83]) 
enrolled infants who had a clinical diagnosis of infantile spasms, a 
hypsarrhythmic EEG or similar, and were no more than 7 days from clinical 
diagnosis. Participants were randomly allocated (1:1) by a secure website to 
receive hormonal therapy with vigabatrin or hormonal therapy alone. Block 
randomisation was stratified for hormonal treatment and risk of developmental 
impairment. Parents and clinicians were not blinded to therapy, but 
investigators assessing electro-clinical outcome were blind to treatment 
allocation. Minimum doses were prednisolone 10mg qds or IM tetracosactide 
depot 0·5mg (40iu) on alternate days with or without vigabatrin 100 mg/kg per 
day. The primary outcome was no observed spasms between days 14 and 42 
inclusive of treatment. Analysis was by intention to treat. The trial is registered 
with The International Standard Randomised Controlled Trial Number (ISRCTN), 
54363174. 
 
 
 4 
 
Findings: 
Between March 7, 2007 and July 2, 2014, 766 infants were screened and of those, 
377 were randomised to hormonal therapy with vigabatrin (186) or hormonal 
therapy alone (191). All 377 infants randomised were assessed for the primary 
outcome. 133 of 186 (71.5%) on hormonal therapy with vigabatrin compared 
with 108 of 191 (56.5%) on hormonal therapy alone (difference 15%, 95% CI = 
5·1% to 24·9%, p = 0·002) had no witnessed spasms between days 14 and 42 
inclusive. Serious adverse reactions occurred in 33 cases (17 on hormonal 
therapy with vigabatrin); there were no deaths  attributable to treatment. 
 
Interpretation: 
Hormonal therapy with vigabatrin is significantly more effective at stopping 
spasms than hormonal therapy alone. The definition of response to treatment 
(absence of spasms from day 14 to 42 inclusive) suggests that the effect seen 
may be sustained, and this will be investigated at the 18 month follow-up.    
        
Funding: 
The Castang Foundation. Additional funding from BURP, NIHR, BRONNER-
BENDER Stiftung/Gernsbach and University Children’s Hospital Zurich.  
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Introduction 
 
Infantile spasms (IS), also known as West syndrome, are a devastating form of 
infantile epilepsy that is difficult to treat and associated with a poor outcome.1 It 
was the first described epileptic encephalopathy – a condition in which the 
epileptic activity itself contributes to cognitive and neurological decline.2  
Infantile spasms have an estimated incidence of approximately 0·43 per 1000 
live births and occur commonly between 3 and 12 months of age with a peak 
incidence around 6-7 months.3  There is a characteristic chaotic and high voltage 
inter-ictal EEG pattern in IS called “hypsarrhythmia” but atypical patterns occur 
and assessment of the EEG pattern has poor inter-rater reliability.5,6 
 
An underlying aetiology, which may be structural (e.g. neuronal migration 
disorders), genetic (e.g. Down’s syndrome), metabolic (e.g. molybdenum co-
factor deficiency) or acquired (e.g. hypoxic ischaemic encephalopathy), is 
identified in 60-70% of cases .7 This percentage will increase with the advent of 
newer genetic investigative techniques.  Tuberous sclerosis complex is the single 
most common underlying cause of IS occurring in 7%.  
 
Neuro-development regresses with the onset of this devastating disorder and 
delayed treatment may lead to worse outcomes. 8-10 Identification of effective, 
swiftly acting treatments is therefore important. Two treatment modalities have 
been most investigated: hormonal therapies and vigabatrin. Since 1958, 
hormonal treatments have been used, initially with intramuscular 
adrenocorticotropic hormone (ACTH) but more recently with a synthetic 
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alternative, tetracosactide depot or with oral corticosteroids.11,12  In the 1990s, 
vigabatrin, an inhibitor of gamma-aminobutyric acid transaminase, was 
introduced in Europe as an effective treatment for IS,13 however, vigabatrin is 
known to be toxic to the retina and can cause visual field defects. This toxicity in 
children is estimated to occur in approximately one fifth of those treated and 
appears to be associated with prolonged treatment of more than 6 months.14, 15 
 
We have previously shown that, when compared to vigabatrin, hormonal 
treatments (prednisolone or tetracosactide depot) are associated with cessation 
of spasms in a higher proportion of infants, and with superior developmental 
scores in those infants who have no identified aetiology for their spasms.12,16,17  
We noticed in that trial that there were some children who, having not 
responded to one treatment, subsequently rapidly responded to the alternate 
treatment. In the International Collaborative Infantile Spasm Study (ICISS), we 
aimed to test our hypothesis that combining hormonal and vigabatrin therapy 
would achieve spasm cessation for 4 weeks between day 14 and 42 of treatment 
in a greater proportion of infants than with hormonal therapy alone.  
 
Methods 
Study design and participants 
ICISS was a multicentre, open-label randomised trial with some blind outcome 
measures, done in 102 hospitals in five countries (Australia [3]: XX; Germany 
[11]: XX; New Zealand [2]: XX; Switzerland [3]: XX; United Kingdom [83]: XX). 
Local investigators enrolled and managed patient assessment and care, including 
determining cessation of spasms.  
 7 
 
Participants were included if they were aged 2–14 months at study enrolment; 
had  a clinical diagnosis of infantile spasms as assessed by the local investigator; 
and had an EEG that was judged by local neurophysiologists to be 
hypsarrhythmic or similar, compatible with the diagnosis of infantile spasms. 
Participants were excluded if they were aged less than 2 months or more than 14 
months; had a delay of more than 7 days since the diagnosis; had a diagnosis of 
tuberous sclerosis, previous treatment for infantile spasms or previous use of 
hormonal treatments or vigabatrin; the coincidence of another condition was 
likely to be lethal before outcome assessment; there was predictable lack of 
availability for follow up for 18 months; the parents or guardians had difficulty 
with language used for assessment; or they were participating in a concurrent 
trial. Written informed consent was obtained from the parents or guardian. 
 
The study protocol was approved by the UK South West Multicentre Research 
Ethics Committee (06/MRE06/21) and all relevant local research ethics 
committees. 
 
 
Randomisation and masking 
Patients were randomized (1:1) to receive hormonal therapy with vigabatrin or 
hormonal therapy alone. Randomisation was done using an interactive computer 
system accessed independently by recruiting clinicians via the trial website. 
Where parents consented, there was an additional randomization of type of 
hormonal therapy used, (1:1, prednisolone or tetracosactide depot). Block 
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randomisation (random block size of less than 10) was used and randomisation 
was stratified on two variables: presence or absence of factors that would 
increase the risk of developmental impairment (one or more of: chromosomal 
abnormality or clinical syndrome, neonatal encephalopathy with seizures, and 
cerebral palsy or developmental impairment diagnosed before onset of spasms) 
and hormonal treatment (prednisolone or tetracosactide depot) randomly 
allocated or chosen by parents. An independent statistician (GT) generated the 
allocation sequences.  
 
The pre-treatment and post-treatment  (obtained between days 14-21 inclusive 
after initiation of treatment) EEGs were assessed blind to treatment and to 
clinical outcome: a majority view of three clinicians (JPO, AL, RN, RP) was 
accepted for determination of the resolution of EEG features supporting the 
diagnosis. Aetiology was determined blind to treatment (FJKO’C and JPO) 
through history, examination and investigation and classified as proven 
(subdivided into prenatal, perinatal, postnatal and other), no aetiology identified, 
or not known if a major piece of information was missing. A study radiologist 
(ML) reviewed MRI scans. 
 
Procedures 
The study treatments were prednisolone (soluble tablets), tetracosactidedepot , 
and vigabatrin. Pyridoxine could only be given to exclude pyridoxine dependent 
seizures. The same products were used in all participating hospitals, and 
although the market authorization holder varied, this did not affect the dose and 
drugs used.  
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Prednisolone was given orally (10 mg four times a day) for 2 weeks. If spasms 
continued on Day 7 or reappeared between Day 8 and Day 14 inclusive, the dose 
was increased to 20 mg three times a day for the remaining doses. 
Tetracosactide depot was given intramuscularly (0·5 mg [40 IU] on alternate 
days) for 2 weeks. If spasms continued on Day 7 or reappeared between Day 8 
and Day 14 inclusive, the dose was increased to 0.75 mg on alternate days for the 
remaining doses. Vigabatrin was given orally in two divided doses per day: 50 
mg/kg per day for the first two doses; increasing to 100 mg/kg per day after 24 h 
and, if spasms continued after a further 72 h, to 150 mg/kg per day. After 2 
weeks of treatment, hormonal therapy was tapered: all children received a 
reducing dose of prednisolone with reductions of 10 mg every 5 days or, if on the 
higher dose of treatment, 40 mg daily, then 20 mg, then 10 mg for 5-day periods. 
Hormonal therapy ceased after Day 29. Vigabatrin continued at the same dose on 
a body weight basis until 3 months from the start of treatment when the dose 
was reduced over 4 weeks. Local investigators were allowed to change treatment 
if that was considered to be in the infant’s best interest and in non-responders. 
Drug accountability was monitored by direct questioning. Parents filled in a daily 
record of spasm frequency for the first 42 days of the trial and there was 
minimum follow up with treating clinicians on days 15 and 43. 
 
 
Outcomes 
The primary outcome was cessation of spasms, which was defined as no 
witnessed spasms on and between Day 14 and Day 42 inclusive from trial entry. 
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Secondary outcomes were time to response (defined as the first day after 
initiation of trial treatment on which spasms were not seen and after which 
response was maintained until Day 42 of treatment); electro-clinical response 
(defined as cessation of spasms and resolution of the EEG features supporting 
the diagnosis i.e. hypsarrhythmia or similar, compatible with the diagnosis of 
infantile spasms); absence of spasms on days 13 and 14; and number of 
responders if single spasms are allowed in responders from Day 14 to 42 
inclusive.  
 
Lead-time refers to the delay between clinical onset of spasms and initiation of 
treatment and was categorized into five time periods (7 days or less, 8 to 14 
days, 15 to 28 days, 29 days to 2 months and greater than 2 months) or as not 
known. Clinical onset of spasms precedes (often by days or weeks) the formal 
diagnosis of IS, which requires physician assessment and EEG confirmation (see 
Figure 2).  
 
Adverse events were assessed by the local investigator and of these, only 
adverse reactions were reported to the trial centre. A Data Monitoring and Ethics 
Committee reviewed recruitment and serious adverse reactions. An adverse 
reaction was defined as any untoward or unintended response thought to be 
related to trial treatments. An adverse reaction was judged serious if it was life-
threatening, caused death, resulted in persistent or significant disability or 
required hospitalization. Causality was determined by the treating clinician. 
Expected adverse reactions were listed in the protocol. During and immediately 
after hormonal treatment, the use of antibiotics—including an anti-
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staphylococcal agent—was recommended for the treatment of fever. Central 
monitoring of data was undertaken by study investigators (JPO, FOC, SE) who 
reviewed the case report forms as they were returned to the trial centre (Bath, 
United Kingdom).  
 
Statistical analysis 
Using the data from our previous clinical trial (UKISS)12,16,17  and using the 
definition of cessation of spasms described above, we estimated that 60% of 
infants would achieve a primary clinical response on hormonal therapies. We 
judged that an improvement in response of 15% (i.e. from 60% to 75%) would 
be considered clinically meaningful. Consequently the number of participants 
required to see an improvement from 60% to 75%, using a two-tailed alpha level 
of 0.05, and 90% power would be 205 in each group, or 150 in each group at 
80% power (see ICISS protocol, section 11.2.1). Recruitment commenced on 
March 7, 2007 and by May 22, 2014, 377 infants had been recruited giving well 
in excess of 80% power. The decision was then taken to halt recruitment, given 
the disproportionate costs and renewed applications for funding that would be 
required to extend the trial to recruit the small number of patients needed to 
reach 90% power.  
 
 
All analyses were by intention to treat. The percentages responding to each 
treatment modality and the difference in percentages with 95% confidence 
intervals are reported. Differences between the hormonal treatment group and 
the hormonal treatment with vigabatrin group for the primary outcome were 
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assessed using logistic regression. Sensitivity analyses controlling for age at 
randomization, sex, and lead-time to treatment were performed.  
 
This study incorporated a patient preference design whereby prednisolone or 
tetracosactide depot were allocated either by randomization or patient 
preference. A further sensitivity analysis was therefore performed to establish 
whether any main treatment effect was consistent however hormonal treatment 
was allocated. A final multivariate model was constructed incorporating the 
main treatment effect, the variables used for stratification in randomisation, and 
whether hormonal treatment was randomized or not. Logistic regression models 
were not over-fitted.18 Statistical analyses were performed using Stata IC 11·2 
(Statacorp, College Station, Texas, USA).  
 
 
 
The trial is registered with The International Standard Randomised Controlled 
Trial Number (ISRCTN), number 54363174; and the European Union Drug 
Regulating Authorities Clinical Trials (EUDRACT), number 2006-000788-27. The 
full protocol is available at www.iciss.org.uk. 
 
Role of funding source 
The sponsor and funding sources of the study had no role in study design, data 
collection, data analysis, data interpretation or writing of the report. The senior 
authors (FJKO’C, JPO, SWE and ALJ) had full access to all the data in the study and 
had final responsibility for the decision to submit for publication. 
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Results 
The trial ran from March 7, 2007 (date of first recruit) until July 2, 2014 (date of 
last primary outcome assessment). 766 infants were assessed for eligibility, of 
whom 377 met the inclusion criteria and were randomised (figure 1). Of these, 
186 were allocated  to hormonal therapy with vigabatrin (combination therapy) 
and 191 were allocated to hormonal therapy alone. One infant allocated 
prednisolone with vigabatrin did not receive vigabatrin and one allocated 
tetracosactide depot (with vigabatrin) received prednisolone (with vigabatrin).  
Eight allocated to tetracosactide depot received tetracosactide non- depot (2 
with vigabatrin). One case allocated to tetracosactide depot with vigabatrin 
withdrew and they were categorized as a non-responder for the purposes of this 
analysis; therefore results from all 377 infants were analysed for the primary 
outcome.  
 
Of the total 377 infants randomised, the treatment was given according to 
protocol in 319 (149 on vigabatrin) infants over the first 14 days and in 349 (171 
on vigabatrin) infants between days 15 and 42 inclusive. There was reason to 
suspect non-adherence to treatment in 19 (10 on vigabatrin). Three patients 
allocated hormonal treatment alone received vigabatrin when tuberous sclerosis 
was diagnosed in two and at parents request in one. Thirty-two received 
pyridoxine to exclude pyridoxine dependent seizures (20 on vigabatrin) and 
seven (four with vigabatrin) received non-trial treatments for their spasms in 
the first 14 days (all received a benzodiazepine). 
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The age range at randomization was 73 to 420 days (median 206 days). There 
were no clinically important imbalances between treatment groups with regard 
to baseline characteristics (Table 1). At trial entry, 55(30 on vigabatrin) were 
receiving a concurrent anti-epileptic for other seizure types. 
 
The primary outcome was assessed in 377 infants. Cessation of spasms occurred 
in 133 of 186 (71·5%) on hormonal treatment with vigabatrin and in 108 of 191 
(56·5 %) on hormonal treatment alone (difference 15%, 95%CI 5·1% to 24·9%; 
chi-squared = 9·15 (1 df), p=0·002).  
 
The treatment effect favouring combination therapy remained significant in a 
logistic regression analysis that controlled for risk of developmental impairment, 
type of hormone treatment, and whether or not hormonal treatment was 
randomized (Odds ratio 2·1 (95% CI 1·3 to 3·2) p = 0·001, Table 2). High risk of 
developmental impairment was the other variable in the multivariable model 
that was significantly associated with the primary outcome (Odds ratio 0.4 (95% 
CI 0·3 to 0·6) p < 0·001, Table 2).  
 
In univariate analyses, the only other variable with a significant relationship 
with the primary outcome—apart from modality of treatment and risk of 
developmental impairment—was lead-time to treatment. There was a clear drop 
in response rate in those infants who had a lead-time to treatment greater than 
two months (Table 3). 
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After stratifying the data by risk of developmental impairment, the effects of 
combination therapy are more clearly seen in those children who were thought 
at the time of randomization to be at low risk for developmental impairment 
(n=170). In this group, cessation of spasms occurred in 54 of 87 (62·1%) on 
hormonal treatment alone and 73 of 83 (88·0%) on combination therapy 
(difference 25.9%, 95%CI 12.6% to 39.2%, chi squared = 15.1 (1 df), p<0.001). In 
the group thought to be at high risk of developmental impairment at 
randomization (n=207), cessation of spasms occurred in 54 of 104 (51·9%) on 
hormonal treatment alone and in 60 of 103 (58·3%) on hormonal treatment with 
vigabatrin (difference 6·4%, 95%CI – 7·4% to + 20·2%, chi squared = 0.84 (1 df) 
p=0·36). 
 
Secondary outcomes were assessed in 377 infants. Treatment response was 
faster on combination therapy (median response time = 2 days, IQR 2-4 days) 
than hormonal therapy alone (median response time = 4 days, IQR 3-6 days, z = 
6·04, p < 0·001, Wilcoxon rank sum test).  
 
Electro-clinical response was achieved in 227 of the 374 infants in whom both 
clinical and electrical outcomes were available (three missing values). 123 of 185 
(66·5%) allocated to combination therapy compared with 104 of 189 (55·0%) 
allocated to hormonal therapy alone achieved an electro-clinical response 
(difference 11·5%, 95% CI 1·4% to 21·6%, chi squared = 5.2 (1 df) p = 0·023). 
The treatment effect favouring combination therapy with respect to electro-
clinical outcome remained in the multivariate logistic regression (Odds ratio 1·7 
(95% CI 1·1 to 2·8) p = 0·015, Table 4). Risk of developmental impairment was 
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also significantly associated with electro-clinical outcome; those thought to be at 
high risk of developmental delay at randomization had significantly reduced 
odds of achieving an electro-clinical response compared to the low risk of 
developmental delay group (Odds ratio 0.5 (95% CI 0.3 to 0.8) p = 0.003). 
 
Cessation of spasms at Days 13 and 14 was achieved in 166 out 186 (89.3%) 
infants treated with combination therapy compared with 132 out of 191 (69.1%) 
in those treated with hormonal therapy alone (difference 20.2%, 95%CI 11.8% 
to 28.6%; chi-squared = 23.2 (1 df), p < 0·001).  57 out of the 298 (19.1%) day 13 
and14 responders had relapsed by Day 42 (33 who had been on combination 
therapy, and 24 who had been on hormonal therapy alone). 
 
The number of responders if single spasms are allowed in responders from Day 
14 to 42 inclusive were 141 out of 186 (75.8%) on combination therapy 
compared with 121 out of 191 (63.4%) on hormonal therapy alone (difference 
12.4%, 95%CI 2.9% to 21.9%; chi-squared = 6.9 (1 df), p=0·009). 
 
Adverse reactions (table 5) were reported in 228 infants (117 on vigabatrin). 
Serious adverse reactions occurred in 33 infants (17 on vigabatrin). There were 
no deaths attributable to trial treatment. Treatment dose was less than expected 
due to an adverse reaction in 17 infants (14 on vigabatrin). Movement disorders 
were reported in 16 infants (14 on vigabatrin). 
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Discussion 
As had been hypothesized, hormonal therapy with vigabatrin (combination 
therapy) compared to hormonal therapy alone was associated with more infants 
achieving the primary outcome of spasm cessation between days 14 and 42 of 
treatment. It also resulted in a shorter time to cessation of spasms and more 
infants achieving electro-clinical response. While the Cochrane review19 of 
infantile spasms had determined that hormonal treatment was the best single 
treatment for the cessation of spasms, this trial has shown that combination 
therapy is superior to hormonal therapy alone.  
 
The aim in treating children with epilepsies is often to avoid using multiple 
agents to minimize side effects. This trial is unusual in using combination 
therapy and showing it to be superior to monotherapy. However, other 
investigators have also found that combinations of therapy may be the most 
effective way of treating severe epilepsy syndromes in childhood.20 Combining 
hormonal therapy with vigabatrin may have a synergistic effect or it may 
effectively treat two different populations of infants: those that will 
preferentially respond to manipulation of GABA levels and those that respond to 
the mechanisms through which hormonal therapies exert their effect perhaps by 
 18 
reducing levels of the pro-epileptogenic neuropeptide, corticoptrophin releasing 
hormone.21 
 
The proportion showing a primary clinical response to combination therapy in 
ICISS (72%) is similar to the proportion showing a primary clinical response to 
hormonal therapy alone in our previous study, UKISS (73%).12 However, the 
definition of cessation of spasms in ICISS is far more stringent than that used in 
UKISS (absence of spasms for a 48-hour period on Days 13 and 14 after starting 
treatment in UKISS vs absence of spasms for a four-week period from Day 14 to 
Day 42 after starting treatment in ICISS). The definition of cessation of spasms 
used in this trial was arrived at following a Delphi consensus exercise amongst 
experts prior to writing the trial protocol.22 If the UKISS definition of clinical 
response is applied to the data from this trial, then the response rates on both 
treatment arms is much higher (89.3% versus 69.1%) and the treatment 
difference (20.2%) between the two arms is even wider. The number of Day 13 
and 14 responders who had relapsed by Day 42 (57 out of 298 i.e 19.1%) 
underlines the validity of using a longer period of time to determine clinical 
response. The use of such a stringent definition increases confidence that the 
primary clinical response seen in this trial is both statistically significant and 
clinically meaningful. 
 
One of the factors used in pre-randomisation stratification was whether there 
was a perceived risk of developmental impairment.  The trial protocol defined 
this risk as any patient who had a proven chromosomal abnormality, a proven 
dysmorphic syndrome diagnosis, a proven diagnosis of cerebral palsy, a previous 
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diagnosis of neonatal encephalopathy with seizures, or a diagnosis of 
developmental impairment already made before the onset of spasms. The 88% 
response rate to combination therapy in those children not defined as being at 
risk of developmental impairment is remarkable given the perceived difficulty in 
treating this disorder and emphasizes the need to consider combination therapy, 
especially in those children in this group who can easily be identified as low-risk 
at the time of diagnosis. 
 
The level of risk of developmental impairment was effectively a proxy for 
aetiology identified/not identified that could only be defined post-hoc as it 
depended upon certain investigations which could only be performed after 
treatment had already been initiated. After analysis of the trial clinical report 
forms and neuroimaging, the underlying aetiology was proven in 219 cases 
(58·1%), and no aetiology was identified in 158 cases (41.9%). As expected, 
there was a strong association between the variables “risk of developmental 
impairment” and “aetiology identified” (Chi squared = 113.3 (1 df), p < 0.001) . 
We used risk of developmental impairment in our analysis as that had been one 
of our stratification criteria but the results are very similar if aetiology identified 
/ not identified is used. In the aetiology not identified group, the early clinical 
response rate to combination therapy was 85·1% and the response rate to 
hormonal therapy alone was 60·2% (difference 24·9%, (95% CI 10·1% to 
39·38%) p < 0·001). This result contrasts with the UKISS data, a smaller study 
where there was no perceived effect of aetiology on rate of cessation of spasms.12 
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Previously, in UKISS, we have shown that longer lead-times to treatment were 
associated with lower developmental quotients but not with lower rates of 
spasm cessation.10,12  The present study, however, suggests that a lead-time of 
greater than 2 months from spasm onset to treatment is associated with a lower 
rate of spasm cessation (Table 3). This result emphasizes the need for clinicians 
to identify and treat infantile spasms as soon as possible. 
 
In this trial, analysis was by intention to treat, and infants were enrolled if their 
treating physicians believed that the child had infantile spasms based upon 
clinical observation and having an EEG compatible with the diagnosis. As such, 
the trial mirrored as closely as possible what would happen in clinical practice 
and the results of the trial are therefore likely to be relevant to clinicians. 
Reporting absence of spasms relied upon parental observation, as recorded in a 
seizure diary, and interpretation of that history by the local clinician. The UKISS 
trial had been criticized, particularly in North America, because it reported 
limited electro-clinical outcome information i.e. the cessation of spasms plus the 
resolution of the hypsarrhythmic EEG or similar.24 In ICISS, we have reported the 
electro-clinical outcome and the superiority of combination therapy remains. 
 
There is no definitive evidence that one form of hormonal treatment is better 
than the other, and in UKISS we found no difference. However, we incorporated 
both treatments into the trial because we are aware that some clinicians have a 
preference for one (particularly ACTH) and we felt we would not have had 
widespread acceptance of the trial if we had excluded tetracosactide.   
Conversely we were aware that many parents dislike the idea of giving 
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intramuscular injections and therefore we felt it necessary to include oral 
prednisolone as a hormonal therapy option. We allowed parents, but not 
clinicians, to choose their hormonal treatment. This was done to protect 
recruitment into the trial for our main comparison (hormonal treatment with or 
without vigabatrin). Therefore it is not possible for us to say, without risk of bias, 
which hormonal treatment was superior either when used as monotherapy or in 
combination with vigabatrin. In Table 4 there is a result that suggests 
prednisolone is associated with significantly less chance of achieving an electro-
clinical response than tetracosactide (Odds ratio 0.6 (95% CI 0.4 to 1.0) p = 0.04) 
,but because of the lack of randomization of hormonal therapy, we feel this result 
should be interpreted with caution.  
 
Adverse reactions are a clinically significant problem with both treatments, but 
no significant differences exist between the groups. There were no deaths 
attributable to treatment in this trial. Previously there has been concern that 
high dose hormonal therapy will impair infants’ ability to fight infection and 
predisposes them to overwhelming sepsis.25 The lack of any such events in this 
trial may reflect a better standard of care for patients involved in a clinical trial. 
As recommended in the trial protocol, we would strongly advise antibiotic 
treatment, including anti-staphylococcal agents, for any child on hormonal 
treatment who becomes febrile.  
 
Retinal toxicity from vigabatrin therapy and consequent visual field defects 
(VFDs) are a legitimate concern. It is impossible to tell whether vigabatrin 
therapy in this trial will have led to any defects, but as VFDs appear to be 
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associated with prolonged therapy, the risk of VFDs in this trial where treatment 
with vigabatrin ceased after 4 months is likely to have been low14,15. Jammoul et 
al. first suggested that vigabatrin mediated retinal toxicity was caused by taurine 
deficiency and suggested taurine supplementation in infants receiving 
vigabatrin26. This recommendation was made two years after the trial started 
and we did not therefore mandate taurine supplementation for those receiving 
vigabtrin. It is possible that some infants will have received taurine but we did 
not record this in the trial.  
 
Movement disorders were reported to us during the trial and were an 
unexpected adverse event. We have already reported on the first ten infants 
notified to us since this was felt to be an important issue.27 We concluded that it 
was not possible to attribute movement disorders to vigabatrin and that they 
were likely related to underlying neurological disease. We did not find that 
movement disorder was related to the MRI changes associated with vigabatrin 
therapy.  
 
ICISS represents the largest study or clinical trial of infantile spasms undertaken 
to date. The obvious strengths of the trial are that it was adequately powered 
and that treatments were randomized. Other strengths were the complete 
follow-up of all 377 infants for the primary outcome, its inclusion criteria that 
closely mimic clinical practice, its stringent definition of the primary clinical 
outcome, and its blind assessment of EEG outcomes. There are, however, some 
unavoidable limitations. Neither patients nor clinicians were blind to treatment 
allocation. In infants it would not be possible to blind allocation to tetracosactide 
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depot, which is given by intramuscular injection. Conceivably, hormonal therapy 
with vigabatrin could have been compared to hormonal therapy with placebo 
but the costs of furnishing trial supplies to all sites for the duration of the trial 
were prohibitive for a non-commercial trial. Clinicians assessing the primary 
clinical outcome were not blinded to treatment allocation, but this would never 
have been possible given that treatment outcome was assessed over a four week 
period by patient diary. Assessors of the electro-clinical outcome were, however, 
blind to treatment allocation and the association between combination therapy 
and improved outcome remained.  
 
A further potential weakness in the study is that investigators, despite the 
directions of the protocol, did not universally record reasons for exclusion 
amongst children who were screened for the study. This could theoretically have 
introduced a selection bias if individual clinicians were systematically biased 
with respect to enrolling some children and not others into the trial. However, 
we think such a bias is unlikely. Firstly, the profile of the trial participants in 
terms of sex, age, proportion with developmental delay at onset, and aetiologies 
was similar to the UKISS trial and to previous epidemiological (population 
based) cohorts of infantile spasm patients.3 Secondly, a total of 151 clinicians 
from 102 sites were responsible for enrolling the 377 patients in the trial across 
five countries with the median number of recruits per centre being two and 
therefore it is difficult to see how any one clinician’s bias with respect to 
recruitment in the trial would be likely to have a significant impact on the overall 
trial. Thirdly, the recruitment rate of approximately 50% of all patents screened 
 24 
compares favourably with previous trials in this area and with other trials in 
similar rare diseases. 
 
Although all 377 infants were followed up for the primary clinical outcome, three 
children did not have EEG data for an electro-clinical outcome. It is unlikely that 
such a small number of missing data will have altered the result seen. Even if all 
three children are classified as non-responders for the electro-clinical outcome 
then the significant result favouring combination therapy remains. 
 
The most obvious question to be resolved by future research is whether 
combination therapy is associated not only with improved rates of spasms 
cessation but also improved development. The rationale for wanting to treat IS 
as rapidly and effectively as possible is because the spasms are distressing and 
also because by doing so we may improve developmental outcome by shortening 
the exposure to the epileptic encephalopathy. We will attempt to answer this 
question when we are able to report on the developmental outcome in this 
cohort at 18 months of age.  Beyond the ICISS trial, it will be important to 
determine whether prednisolone or tetracosactide depot is more effective when 
combined with vigabatrin. The fact that hormonal therapies were predominantly 
not randomized in this trial precludes a reliable answer to that question from 
this data set but it remains an important question to resolve. In North America 
there still remains a belief, albeit on imperfect evidence, that use of ACTH is 
preferable to oral corticosteroids.28,29 Although the majority of infants in this 
study obtained a clinical response, there is still a significant minority who did not 
respond to combination therapy and the question of what is the next line of 
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therapy for non-responders is unclear. Finally, there has recently been a number 
of genes associated with the development of IS and increasing knowledge of the 
mode of action of their gene products.30-32 Specific therapies targeted to specific 
genetic defects may be a promising avenue for research but the results may not 
be relevant for the majority of IS cases for whom combination therapy is likely to 
be the best initial option for treatment. 
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Research in context: 
 
Evidence before this study: 
 
We have conducted a Cochrane systematic review into the treatment of infantile 
spasms17 that we have continued to update to 31 December 2015. In identifying 
research in the area we search the Cochrane Epilepsy Group Specialised Register 
(31 December 2015), CENTRAL, MEDLINE (up to 31 December 2015), and the 
reference lists of all retrieved articles. We used the search terms “infantile 
spasms” “West syndrome” “West’s syndrome”, “salaam spasm”, 
“hypsarrhythmia”, “randomized controlled trial”, “controlled clinical trial”, and 
“clinical trial”. There were no language restrictions to the search. We have found 
19 small RCTs (fewer than 100 patients enrolled) and 2 larger RCTs (more than 
100 patients enrolled) that have looked at a total of 12 different pharmaceutical 
agents. Overall there are problems with the methodological quality of the 
studies: only two studies had > 100 participants and only one of the studies was 
adequately powered. Only 7 stated their method of randomization and only 4 
reported concealment of allocation. The most popular and commonly used 
treatment modalities are either hormonal treatments (prednisolone, natural or 
synthetic ACTH) or vigabatrin. The strongest evidence suggests that hormonal 
treatment (prednisolone or tetracosactide depot) leads to resolution of spasms 
faster and in more infants than does vigabatrin, although responses without 
subsequent relapse may be no different.11 The same study suggests that 
hormonal treatments might improve the long-term developmental outcome 
compared with vigabatrin in infants not found to have an underlying cause for 
their spasms.15,16 There is no conclusive evidence of superiority for any 
particular type of hormonal therapy (i.e. ACTH versus oral prednisolone), 
although a recent RCT comparing oral prednisolone versus IM ACTH suggested 
prednisolone was more effective at achieving electro-clinical remission.33   
 
Added value of this study: 
 
This study, with 377 randomised paticipants, is the largest treatment trial of 
infantile spasms to date. It is the first study to trial a combination of therapies 
(hormonal therapies plus vigabatrin) versus the current therapeutic modality 
with the best evidence for effectiveness. It also uses a stringent criteria for 
clinical and electroclinical outcome that is relevant to clinical practice. It has 
found that combination therapy is more effective and faster at achieving both 
clinical and electro-clinical responses in children with infantile spasms. 
 
Implications of all the available evidence: 
 
This study has implications for clinicians treating children with infantile spasms. 
It suggests a modality of treatment that will stop spasms faster and in more 
children than has previously been achieved with existing treatment strategies 
and therefore will potentially lessen the long-term detrimental impact of this 
devastating epileptic encephalopathy on both development and future epilepsy 
control.  
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Table 1. Baseline demographic and clinical characteristics 
 Prednisolone 
 
 
(131) 
Tetracosactide 
Depot 
 
(60) 
Total 
Hormonal 
Alone 
 
(191) 
Prednisolone 
with 
vigabatrin 
(135) 
Tetracosactide 
Depot with 
Vigabatrin 
(51) 
Total 
Hormonal 
with 
vigabatrin 
(186) 
Sex       
    Female 53 (40%) 27 (45%) 80 (42%) 59 (44%) 28 (55%) 87 (47%) 
    Male 78 (60%) 33 (55%) 111 (58%) 76 (56%) 23 (45%) 99 (53%) 
 
Age at 
randomisation 
In days 
 
    60-119 6 (5%) 2 (3%) 8 (4%) 9 (7%) 8 (16%) 17 (9%) 
   120-179 40 (31%) 17 (28%) 57 (30%) 31 (23%) 11 (22%) 42 (23%) 
   180-239 38 (29%) 25 (42%) 63 (33%) 51 (38%) 19 (37%) 70 (38%) 
   >=240 47 (36%) 16 (27%) 63 (33%) 44 (33%) 13 (25%) 57 (31%) 
 
Lead time to 
Treatment 
 
   Up to 7 days 42 (32%) 14 (23%) 56 (29%) 40 (30%) 14 (27%) 54 (29%) 
   8-14 days 21 (16%) 15 (25%) 36 (19%) 23 (17%) 13 (25%) 36 (19%) 
   15-28 days 30 (23%) 12 (20%) 42 (22%) 27 (20%) 10 (20%) 37 (20%) 
   29 days to 2 
months 
13 (10%) 14 (23%) 27 (14%) 25 (19%) 8 (16%) 33 (18%) 
   More than 2 
months 
24 (18%) 5 (8%) 29 (15%) 18 (13%) 6 (12%) 24 (13%) 
   Not known 1 (1%) 0  1 (1%) 2 (1%) 0 2 (1%) 
 
Risk of 
developmental 
impairment 
 
   Yes 72 (55%) 32 (53%) 104 (54%) 72 (53%) 31 (61%) 103 (55%) 
   No 59 (45%) 28 (47%) 87 (46%) 63 (47%) 20 (39%) 83 (45%) 
 
Anti epileptic 
drugs for other 
seizure types 
 
   None 113 (86%) 53 (88%) 166 (87%) 113 (84%) 43 (84%) 156 (84%) 
   One 15 (11%) 5 (8%) 20 (10%) 13 (10%) 6 (12%) 19 (10%) 
   2 or more 3 (2%) 2 (3%) 5 (3%) 9 (7%) 2 (4%) 11 (6%) 
 
Pyridoxine 
given to 
exclude 
dependent 
seizures 
 
9 (7%) 
 
3 (5%) 12 (6%) 
 
13 (10%) 
 
7 (14%) 20 (11%) 
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Table 2: Logistic regression model for primary clinical outcome  
 
 
Parameters: 
 
Clinical response (1=response, 0=no response) 
Treatment modality (1=combination therapy, 0=Hormonal therapy) 
Developmental impairment (1=high risk, 0=lower risk) 
Hormone type (1 = prednisolone, 0 = tetracosactide depot) 
Hormone randomized (1 = randomly allocated, 0 = hormone chosen) 
 
Number of observations in model: 377  
Likelihood ratio Chi2 (4 degrees of freedom): 30.34, p < 0.0001 
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Table 3 
 
Lead-time to treatment and response rate* 
 
 
 
Lead-time 
category 
Non-responder Responder Total 
< 7 days 33 (30%) 77 (70%) 110 
8-14 days 25 (35%) 47 (65%) 72 
15-28 days 24 (30%) 55 (70%) 79 
29 days-2 mos. 22 (37%) 38 (63%) 60 
> 2 months 30 (57%) 23 (43%) 53 
Total 134 240 374 
 
Chi2 for trend = 6.06, df = 1, p = 0.0138 
 
*Lead-time to treatment not recorded in 3 cases (2 non-responders, 1 
responder) 
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Table 4: Logistic regression model for electro-clinical secondary outcome  
 
 
 
 
 
Parameters:  
Electro-clinical response (1=response, 0=no response) 
Treatment modality (1=combination therapy, 0=Hormonal therapy) 
Developmental impairment (1=high risk, 0=lower risk) 
Hormone type (1 = prednisolone, 0 = tetracosactide depot) 
Hormone randomized (1 = randomly allocated, 0 = hormone chosen) 
 
Number of observations in model: 374 (3 with electro-clinical outcome missing) 
Likelihood ratio Chi2 (4 degrees of freedom): 19.05, p = 0.0008 
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Table 5 Adverse Reactions 
Number of infants and percentages with adverse reactions during Days 0-42 
from entry inclusive. The bold asterisked numbers in brackets indicate the 
numbers that were serious adverse reactions. P=prednisolone, T=tetracosactide 
depot, H=hormonal treatments combined, P&V=prednisolone with Vigabatrin, 
T&V=tetracosactide depot with Vigabatrin and H&V= hormonal treatments 
combined also with Vigabatrin. U=an unexpected adverse reaction.  required 
treatment to prevent infection or was infected 
 
 
Specific Adverse 
Reactions  P T H  P&V T&V H & V 
Total study number of 
infants 131  60 191 135 51 186 
Allergic rash or anaphylaxis 0 1 (2%) 1 (1%) 0 0 0 
Drowsiness 3 (2%) 0 3 (2%) 33(24%)(*3) 12(24%)(*1) 45(24%)(*4) 
Endocrine/Metabolic 
Disturbance 1 (1%) 1 (2%) 2(1%) 1 (1%) 0 1 (1%) 
Fluid/Electrolyte disturbance 13(10%)(*1) 10(17%)(*2) 23(12%)(*3) 7(5%) 5(10%)(*1) 12(6%)(*1) 
Gastro-intestinal upset 20(15%)(*1) 6(10%)(*1) 26(14%)(*2) 17(13%)(*1) 6(12%)(*1) 23(12%)(*2) 
Hypertonia 3 (2%)(*1) 6 (10%) 9(5%)(*1) 0 3(6%)(*1) 3 (2%)(*1) 
Hypotonia 8 (6%)(*1) 0 8(4%)(*1) 4 (3%) 3 (6%) 7 (4%) 
Immunosuppression 3 (2%)(*2) 0 3 (2%)(*2) 3(2%)(*2) 0 3 (2%)(*2) 
Increased appetite 36 (27%) 15 (25%) 51 (27%) 25 (19%) 10 (20%) 35 (19%) 
Infection 11(8%)(*4) 8(13%)(*1) 19(10%)(*5) 10(7%)(*4) 4(8%) 14(8%)(*4) 
Irritability 54(41%)(*2) 21(35%)(*1) 75(39%)(*3) 45(33%)(*1) 16(31%)(*1) 61(33%)(*2) 
Neuropsychiatric (disturbed 
sleep) 27(21%)(*1) 8(13%) 35(18%)(*1) 22(16%) 7(14%) 29(16%) 
Varicella zoster (chicken pox) 4(3%)(*1) 0 4(2%)(*1) 2(1%)(*1) 0 2(1%)(*1) 
Weight gain 23(18%) 11(18%) 34(18%) 16(12%) 8(16%) 24(13%) 
(U) Abnormal eye movements 0 0 0 1(1%) 0 1(1%) 
(U) Blood disorder - high 
platelet count 0 0 0 0 1(2%) 1(1%) 
(U) Bradycardia 0 0 0 0 1(2%) 1(1%) 
(U) Abnormal breathing pattern 1(1%) 0 1(1%) 0 0 0 
(U) High signal in basal ganglia  1(1%) 0 1(1%) 2(1%) 0 2(1%) 
(U) Hypoxic 1(1%) 0 1(1%) 0 0 0 
(U) Movement disorder 2(2%) 0 2(1%) 8(6%) 6(12%)(*3) 14(8%)(*3) 
(U) Not focusing 0 0 0 1(1%) 0 1(1%) 
(U) Obstructive cardiac 
hypertrophy 1(1%)(*1) 0 1(1%)(*1) 0 0 0 
(U) Pallor 1(1%) 0 1(1%) 0 0 0 
(U) Squinting 1(1%) 0 1(1%) 0 0 0 
(U) Sweating 0 1(2%) 1(1%) 1(1%) 0 1(1%) 
(U) Tachypnoea 1(1%) 0 1(1%) 0 0 0 
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Figure 1. Trial Profile 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility (n=766) 
Excluded  (n=389) 
   Reasons for exclusion not recorded 
Analysed  (n=191) 
 Excluded from analysis (n=0) 
Lost to follow-up (n= 0) 
 
Allocated to intervention (n=191) 
 Received allocated intervention (n=191, 60 
Tetracosactide depot, 131 Prednisolone) 
 Did not receive allocated intervention (n= 0) 
Received Vigabatrin in addition (n=3) 
 Incomplete compliance e.g. did not receive  
   recommended dose (n= 9) 
 
Lost to follow-up (n= 1, parental request to 
withdraw) 
Allocated to intervention (n=186) 
 Received allocated intervention (n=185, 51 
Vigabatrin with Tetracosactide depot, 134 
Vigabatrin with Prednisolone) 
 Did not receive allocated intervention (n=1, 
parental change of mind) 
 Incomplete compliance e.g. did not receive  
   recommended dose (n= 10) 
 
 
Analysed  (n=186) 
 Excluded from analysis (n=0, parental 
decision to withdraw=1 but included in 
analysis and coded as non-responder) 
 
Allocation 
Analysis 
Follow-Up 
Enrolled and Randomized (n=377) 
Enrolment 
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Figure 2 
 
